Ori Segal1, Michael Mimouni2, Gilad Rabina3, Roy Yavnieli2, Arie Y Nemet4. 1. Department of Ophthalmology, Meir Medical Center, Kfar Sava and the Sackler School of Medicine, Tel Aviv University, Kfar Saba, 44281, Israel. orisegal@gmail.com. 2. Department of Ophthalmology, Rambam Health Care Campus and the Technion-Israel Institute of Technology, Haifa, Israel. 3. Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Department of Ophthalmology, Meir Medical Center, Kfar Sava and the Sackler School of Medicine, Tel Aviv University, Kfar Saba, 44281, Israel.
Abstract
PURPOSE: To identify baseline optical coherence tomography (OCT) factors in ischemic central retinal vein occlusion (CRVO) that predict response to bevacizumab injections. METHODS: Patients underwent OCT at diagnosis and the central macular thickness, subretinal fluid width and height as well as the presence of intraretinal cysts were measured. The extent of disorganized retinal inner layers, outer plexiform layer (OPL), external limiting membrane, ellipsoid zone and cone outer segment tips (COST) was recorded. Patients received three consecutive monthly injections of bevacizumab followed by pro re nata treatment. RESULTS: Overall 32 eyes of 32 patients aging 69.4 ± 12.7 years were included. In univariate correlational analyses baseline OPL disruption (- 41, p = 0.02), EZ disruption (r = - 0.36, p = 0.05) and COST disruption (r = - 0.37, p = 0.04) correlated with deterioration in BCVA at 1 year. Partial least squares demonstrated that the factors most largely associated with deterioration in BCVA were COST disruption and OPL disruption followed by EZ disruption, while worst vision at baseline was associated with improvement in vision. CONCLUSION: In patients with ischemic CRVO treated with bevacizumab, BCVA improvement at 1 year can be partially predicted from baseline OCT measurements by the extent of COST, OPL and EZ disruption.
PURPOSE: To identify baseline optical coherence tomography (OCT) factors in ischemic central retinal vein occlusion (CRVO) that predict response to bevacizumab injections. METHODS:Patients underwent OCT at diagnosis and the central macular thickness, subretinal fluid width and height as well as the presence of intraretinal cysts were measured. The extent of disorganized retinal inner layers, outer plexiform layer (OPL), external limiting membrane, ellipsoid zone and cone outer segment tips (COST) was recorded. Patients received three consecutive monthly injections of bevacizumab followed by pro re nata treatment. RESULTS: Overall 32 eyes of 32 patients aging 69.4 ± 12.7 years were included. In univariate correlational analyses baseline OPL disruption (- 41, p = 0.02), EZ disruption (r = - 0.36, p = 0.05) and COST disruption (r = - 0.37, p = 0.04) correlated with deterioration in BCVA at 1 year. Partial least squares demonstrated that the factors most largely associated with deterioration in BCVA were COST disruption and OPL disruption followed by EZ disruption, while worst vision at baseline was associated with improvement in vision. CONCLUSION: In patients with ischemic CRVO treated with bevacizumab, BCVA improvement at 1 year can be partially predicted from baseline OCT measurements by the extent of COST, OPL and EZ disruption.
Authors: Franco M Recchia; Ingrid U Scott; Gary C Brown; Melissa M Brown; Allen C Ho; Michael S Ip Journal: Ophthalmology Date: 2010-09 Impact factor: 12.079
Authors: Peter A Campochiaro; David M Brown; Andrew Pearson; Sanford Chen; David Boyer; Jose Ruiz-Moreno; Bruce Garretson; Amod Gupta; Seenu M Hariprasad; Clare Bailey; Elias Reichel; Gisele Soubrane; Barry Kapik; Kathleen Billman; Frances E Kane; Kenneth Green Journal: Ophthalmology Date: 2012-06-21 Impact factor: 12.079
Authors: Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio Journal: Ophthalmology Date: 2011-06-29 Impact factor: 12.079
Authors: David M Brown; Jeffrey S Heier; W Lloyd Clark; David S Boyer; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Rupert Sandbrink; Xiaoping Zhu; Julia A Haller Journal: Am J Ophthalmol Date: 2012-12-04 Impact factor: 5.258